Showing 3871-3880 of 4165 results for "".
- Study: Dry Eye Disease Signs and Symptoms Significantly Reduced with Ciclosporin A 0.1% Cationic Emulsionhttps://modernod.com/news/study-dry-eye-disease-signs-and-symptoms-significantly-reduced-with-ciclosporin-a-01-cationic-emulsion/2480734/Santen EMEA has announced the results of PERSPECTIVE, a real-world evidence study evaluating the long-term treatment of severe keratitis in adult dry eye disease (DED) patients. The study, which was conducted across 44 ophthalmology clinics in 5 European countries, demonstrated that ciclosporin A
- Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI Surgical System in Pseudophakic Eyes with Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-first-patient-treated-in-trident-european-trial-to-evaluate-the-omni-surgical-system-in-pseudophakic-eyes-with-open-angle-glaucoma/2480722/Sight Sciences announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject (Glaukos), in
- Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)https://modernod.com/news/kiora-pharmaceuticals-granted-orphan-drug-designation-for-kio-301-an-investigational-drug-for-the-treatment-of-retinitis-pigmentosa-rp/2480706/Kiora Pharmaceuticals has received orphan drug designation from the FDA for its investigational treatment of retinitis pigmentosa, KIO-301. Kiora expects to initiate clinical trials of KIO-301 in Q3 2022. Orphan drug designation provides for facilitated development discussions with the FDA,
- RG6501 (OpRegen) Full Phase 1/2a Results to Be Presented at ARVO Annual Meetinghttps://modernod.com/news/rg6501-opregen-full-phase-12a-results-to-be-presented-at-arvo-annual-meeting/2480697/Lineage Cell Therapeutics announced that full results from a phase 1/2a clinical study of RG6501 (OpRegen), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Associ
- Tarsus Appoints José Trevejo, MD, PhD, Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-jose-trevejo-md-phd-chief-medical-officer/2480613/Tarsus Pharmaceuticals announced the appointment of José Trevejo, MD, PhD, as Chief Medical Officer. Dr. Trevejo brings over 20 years of experience advancing the clinical development of novel therapeutics for serious diseases. Dr. Trevejo’s leadership will be highly valued
- AI Can Identify Heart Disease From an Eye Scanhttps://modernod.com/news/ai-can-identify-heart-disease-from-an-eye-scan/2480602/Scientists have developed an artificial intelligence system that can analyze eye scans taken during a routine visit to an optician or eye clinic and identify patients at a high risk of a heart attack, according to a University of Leeds, UK, news release. Doctors have recognized th
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-36-months-in-phase-2b-study/2480567/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 36-month analysis of the phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. <
- Aramis Biosciences Receives FDA Clearance to Proceed with Phase 2 Trail of A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-receives-fda-clearance-to-proceed-with-phase-2-trail-of-a197-a-novel-immunomodulatory-agent-for-the-treatment-of-dry-eye-disease/2480558/Aramis Biosciences announced that the FDA has cleared the investigational new drug (IND) application for A197, enabling the company to proceed with a phase 2 proof of concept clinical trial. “We are pleased that FDA has cleared A197 to move into phase 2 clinica
- Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseaseshttps://modernod.com/news/ray-therapeutics-closes-6m-seed-financing-to-advance-novel-optogenetics-platform-to-treat-blinding-diseases/2480549/Ray Therapeutics, a developer of optogenetic gene therapies for patients with blinding diseases, announced the closing of a $6 million seed financing round, led by 4BIO Capital. The funding will be used to advance its optogenetic therapy, Ray-001, into clinical trials in retinitis
- GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral Lumevoq Injections at 2-Year Follow-Up of REFLECT Phase 3 Trialhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-bilateral-lumevoq-injections-at-2-year-follow-up-of-reflect-phase-3-trial/2480513/GenSight Biologics reported topline efficacy and safety results at 2 years post-treatment administration in the REFLECT Phase 3 clinical trial with Lumevoq. The results show sustained efficacy and safety for bilateral intravitreal injection of the gene therapy, including better efficacy compared